Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer

Haratani, Koji; Hayashi, Hidetoshi; Chiba, Yasutaka; Kudo, Keita; Yonesaka, Kimio; Kato, Ryoji; Kaneda, Hiroyasu; Hasegawa, Yoshikazu; Tanaka, Kaoru; Takeda, Masayuki; Nakagawa, Kazuhiko

doi:10.1001/jamaoncol.2017.2925

Public

Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer

Published in JAMA Oncology • Oct 3, 2017

Authors:

Koji Haratani

Hidetoshi Hayashi

Yasutaka Chiba

Abstract

IMPORTANCE: Immune-related adverse events (irAEs) have been associated with the efficacy of PD-1 (programmed cell death protein 1) inhibitors in patients with melanoma, but whether such an association exists for non-small-cell lung cancer (NSCLC) has remained unknown. OBJECTIVE: To evaluate the rela...

Subject

Medicine

Nivolumab

Internal medicine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!